Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:33 2025-01-14 am EST			5-day change	1st Jan Change
90.11 ^CHF	-0.75%		-0.32%	+1.58%

Jan. 13	Swiss Stocks Close Lower Ahead of Key Inflation, Economic Data	MT
Jan. 13	Global markets live: Apple, Johnson & Johnson, Meta, Amazon, The Hershey, Eli Lilly...

New Phase IIIB data shows Novartis Fabhalta(R) improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

December 06, 2024 at 01:15 am EST

(MORE TO FOLLOW) Dow Jones Newswires

December 06, 2024 01:15 ET (06:15 GMT)

Latest news about Novartis AG

Swiss Stocks Close Lower Ahead of Key Inflation, Economic Data	Jan. 13	MT
Global markets live: Apple, Johnson & Johnson, Meta, Amazon, The Hershey, Eli Lilly...	Jan. 13
Illumina Starts Pilot Program With Partners to Generate Proteomics Data	Jan. 13	MT
Novartis: Favourable court ruling on Entresto	Jan. 13	CF
Novartis's U.S. Patent for Entresto Upheld by Appeals Court	Jan. 13	DJ
US Court Upholds Validity of Novartis' Combination Patent for Entresto	Jan. 13	MT
Novartis Entresto(R) US patent upheld by US Court of Appeals	Jan. 13	DJ
NOVARTIS AG : Goldman Sachs remains Neutral	Jan. 09	ZD
Light Horse Therapeutics Inc announced that it expects to receive $87 million in funding from Versant Venture Management, LLC, Bristol-Myers Squibb Company, AbbVie Ventures, Inc., Taiho Ventures, LLC, Mubadala Capital, Novartis AG	Jan. 08	CI
NOVARTIS AG : Gets a Neutral rating from Berenberg	Jan. 07	ZD
NOVARTIS AG : Bernstein reiterates its Buy rating	Jan. 07	ZD
A poor 2024 increases the odds of a brighter 2025	Jan. 02
Experts expect more IPOs and takeovers in 2025	Jan. 02	RE
Swiss Stocks Close Higher Ahead of New Year Break	Dec. 30	MT
Novartis Says Gene Therapy for Spinal Muscular Atrophy Meets Primary Endpoint in Phase 3 Study	Dec. 30	MT
Novartis' Late-stage Study for Spinal Muscular Atrophy Therapy Meets Primary Endpoint	Dec. 30	MT
Novartis' Late-stage Study for Spinal Muscular Atrophy Therapy Meets Primary Endpoint	Dec. 30	MT
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA	Dec. 30	DJ
Novartis Announces Positive Topline Results from the Phase III Steer Study	Dec. 30	CI
Sector Update: Health Care Stocks Lower in Late Afternoon Trading	Dec. 27	MT
Sector Update: Health Care	Dec. 27	MT
Novartis Must Face Claims Alleging Kickbacks for MS Drug Promotion, US Appeals Court Rules	Dec. 27	MT
Novartis Must Face Claims Alleging Kickbacks for MS Drug Promotion, Appeals Court Rules	Dec. 27	MT
Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rules	Dec. 27	RE
Novartis to Close MorphoSys Sites, Affecting 330 Jobs	Dec. 19	MT

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Employees

76,057

Sector

Pharmaceuticals

Calendar

2025-01-31 - Q4 2024 Earnings Release

More about the company